Post-translational modification of Bcl-2 protein has been described in a variety of cell models with effects varying from enhanced to abrogated function. In this study, we demonstrated that Bcl-2 was constitutively phosphorylated in several hematopoietic tumor cell lines and in primary ALL cells. Increased phosphorylation of Bcl-2 protein in the JM1 ALL cell line, achieved by expression of the phosphomimetic Bcl-2 construct S70E, enhanced JM1 cell chemoresistance. In contrast, initiation of JM1 cell apoptosis was coincident with dephosphorylation of Bcl-2 and elevated protein phosphatase 2A activity. S70E expression also diminished tBid-mediated cytochrome c release and blunted chemotherapy-induced activation of caspases-9 and -3 in JM1 cells. To determine whether soluble factors produced by stromal cells in the bone marrow influence phosphorylation of Bcl-2 protein, a panel of recombinant cytokines was evaluated. Of those tested, vascular endothelial growth factor (VEGF) induced phosphorylation of Bcl-2 protein and blunted cytochrome c release during chemotherapy or tBid treatment of ALL cells. In contrast, JM1 cells transfected with S70A, resulting in expression of Bcl-2 protein that cannot be phosphorylated, were not efficiently rescued from apoptosis by VEGF. These observations suggest that optimal protection of leukemic cells by VEGF may require activation of a pathway that includes Bcl-2 phosphorylation.
Introduction
Originally identified by its role in follicular lymphoma, 1, 2 Bcl-2 has long been recognized as a critical protein in regulation of the apoptotic pathway. However, it has become increasingly evident that the activity of Bcl-2, distinct from total expression level, may provide additional insight into the mechanisms by which it regulates cell survival. Recent reports have documented conversion of Bcl-2 from an antiapoptotic to a proapoptotic factor by cleavage of the native 26 kD protein to a 23 kD product in myeloid and lymphoid leukemic cell lines. 3, 4 In addition to proteolytic inactivation, post-translational modification via phosphorylation either at serine 70, or at multiple sites located in the flexible loop domain, has been associated with decreased Bcl-2 activity. Antimicrotubulin agents, proteasome inhibitors, okadaic acid, kainic acid, arsenic trioxide, 2-methoxyestradiol, cryptophycin and all-trans retinoic acid have been shown to induce Bcl-2 phosphorylation at serine 70 with subsequent induction of cell death. [5] [6] [7] [8] [9] [10] [11] [12] In contrast, optimal activity of Bcl-2 has also been shown to require phosphorylation in unique settings. It has been reported that phosphorylation of Bcl-2 in the IL-3-dependent murine pre-B REH cell line enhanced survival during growth factor deprivation as well as during exposure to etoposide. 13 Interestingly, a recent report from the same laboratory ascribed the protective role of phosphorylated Bcl-2 in this setting to regulation of intracellular reactive oxygen species and subsequent modulation of cell cycle progression.
14 Expression of phosphomimetic Bcl-2 mutants with either single site phosphorylation of serine 70, or multisite phosphorylation at T69, S70 and S87 in NSF/N1.H7 cells correlated with upregulation of p27 and accumulation of cells in G0/G1 of the cell cycle.
14 Increased Bcl-2 activity was also observed in Hela cells in which phosphorylation of Bcl-2 in G2/M phase-arrested cells following photodynamic therapy with hypericin delayed the onset of apoptosis. 15 Several groups have demonstrated that bone marrow stromal cells play an important role in regulating leukemic cell survival and response to chemotherapy. [16] [17] [18] [19] [20] While the importance of the bone marrow microenvironment in progression of this disease is not disputed, several details of the survival pathways initiated by bone marrow stromal cells remain to be elucidated. Prompted by the reports noted previously, we sought to investigate whether stromal cell signals alter phosphorylation of Bcl-2. Collectively, our data suggest a role for vascular endothelial growth factor (VEGF) regulation of Bcl-2 phosphorylation and chemoresistance in human ALL cells.
Materials and methods

Chemotherapeutic agents
Cytarabine (ara-C, Sigma, St Louis, MO, USA) was stored at 10 mg/ml and etoposide (VP-16, Bristol Laboratories, Princeton, NJ, USA) at a stock concentration of 39.98 mM at À201C. Doxorubicin (Dox, 3 mM) was from Gensia (Irvine, CA, USA) and 4-hydroperoxycyclophosphamide (4-HC, 10 mg/ml) was a gift from Dr T Ball (University of California, San Diego).
Kinase activators and inhibitors
Protein kinase C activators phorbol-12-myristate-13-acetate (PMA) and bryostatin-1 were from Sigma, whereas PKC agonist SC-10 was purchased from Calbiochem (La Jolla, CA, USA). PKC inhibitors bisindolylmaleimide I (Bis), Gö 6983 and staurosporine (Stauro) and additional serine/threonine kinase inhibitors, PKA inhibitor H-89, CaM II inhibitor KN-93, and CDK inhibitor Roscovitine (Ros) were also obtained from Calbiochem. PI-3 kinase inhibitor LY294002 (LY) and MEK/ MAPKs inhibitor PD98059 (PD) were obtained from Cell Signaling Technology (Beverly, MA, USA).
Recombinant growth factors
All growth factors were used at a concentration of 100 ng/ml. Truncated Bid was used at a final concentration of 200 ng/ml.
Antibodies
Rabbit polyclonal antiphospho-Bcl-2 (#2871), rabbit polyclonal anticaspase-9 (#9502), rabbit polyclonal anticytochrome c (#4272) and rabbit polyclonal antiphospho-PKC (#9921) antibodies were purchased from Cell Signaling Technology. Humanspecific Bcl-2 monoclonal antibody (#sc-509) was from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Rat anti-mouse Bcl-2 (clone # 121529), and mouse anti-human VEGF (clone # 9016) antibodies were obtained from R&D Systems. Rabbit polyclonal anticaspase-3 (#67345X) and anticytochrome c oxidase subunit II (COX subunit II; #A-6404) antibodies were purchased from BD Pharmingen. Mouse monoclonal anti-Mcl-1 (sc-12756) antibody was purchased from Santa Cruz, and mouse monoclonal anti-GAPDH (clone #6C5) antibody was obtained from RDI (Research Diagnostics Inc. Flanders, NJ, USA). HRP-conjugated anti-mouse, anti-rat and anti-rabbit secondary antibodies were provided by Amersham (Piscataway, CA, USA) or Santa Cruz.
Cell lines
Human pre-B leukemia cell lines JM1 (ATCC# CRL-10423), RS4;11(ATCC # CRL-1873) and Sup-B15 (ATCC# CRL-1929), and acute T-cell leukemia cell line Jurkat (ATCC# TIB-152), acute promyelocytic leukemia HL-60 (ATCC# CCL-240), multiple myeloma U266B1 (ATCC# TIB-196), breast adenocarcinoma MCF-7 (ATCC# HTB-22) and ovarian epithelial adenocarcinoma OVCAR-3 cell lines (ATCC# HTB-161) were obtained from ATCC (Manassas, VA, USA). Primary ALL cells were provided by the Children's Oncology Group (COG) Tissue Bank (University of Florida). Establishment of human bone marrow stromal cells by our laboratory has been previously described in detail. 21 Murine pro-B cell clone, C1.92, provided by Dr Kenneth S Landreth (West Virginia University), has been previously described. 22 
Bcl-2 constructs and transfection
Plasmids encoding various murine Bcl-2 sequences used in the current study were generously provided by Dr W Stratford May, Jr (University of Florida, Shands Cancer Center) and their construction has been previously described in detail. 23 For 24 h before transfection, JM1 cells were grown in Iscove's Modification of Dulbecco's Medium (IMDM) supplemented with 10% FBS (ATCC). For each transfection, 20 mg of plasmid DNA was diluted in 500 ml of serum-free D-MEM. Cells were rinsed and then maintained at 371C for 24 h prior to long-term G418 selection (2 mg/ml).
Concentration of tumor cell and stromal cell conditioned medium (CM)
Confluent human-derived bone marrow stromal cells were incubated for 24 h, or JM1 cells (1 Â 10 6 /ml) for 8 h in serum-free 
Western blot analyses
Proteins were resolved on SDS-PAGE gels and transferred to nitrocellulose membranes. Membranes were blocked in TBS/5% nonfat dry milk/0.05% Tween-20 at room temperature for 1 h and probed with the indicated primary antibodies. Following incubation with HRP-conjugated secondary antibodies signal was visualized using ECL reagents (Amersham, Piscataway, NJ, USA).
In vitro dephosphorylation with lPpase
Treatment of cell lysates with Lambda protein phosphatase (lPPase) was performed according to the protocols provided by the manufacturer (Sigma, St Louis, MO, USA).
Immunoprecipitation and in vitro cleavage of Bcl-2 with active caspase-3 JM1 cells expressing either wild type (WT), S70A or S70E murine Bcl-2 were lysed in complete cell lysis buffer (CCLB). Insoluble cell debris was removed by centrifugation and protein concentrations were quantitated. Prior to immunoprecipitation, 1 mg murine anti-Bcl-2 antibody was bound to protein A/G-conjugated Sepharose beads at 41C overnight, washed with CCLB twice and incubated with 200 mg total protein for 2 h. Following additional washes with CCLB and caspase-3 reaction buffer the immunocomplexes were resuspended in 20 ml of caspase-3 reaction buffer containing 1 mg of recombinant active mouse caspase-3 (BioVision, Mountain View, CA, USA).
PP2A activity assay
Protein phosphatase 2A (PP2A) activity was evaluated by determining the generation of free phosphate from a short synthetic phosphopeptide substrate of serine/threonine protein phosphatases using the molybdate green-phosphate complex assay (Promega, Madison, WI, USA) as previously described. 24 
Annexin-V-FITC staining
To evaluate apoptosis, cells were stained with FITC-conjugated annexin-V using the TACS apoptosis detection kit (R&D systems, Minneapolis, MN, USA) as recommended by the manufacturer. Following staining, cells were evaluated by flow cytometry and data analyzed using CellQuest software (Becton Dickinson, San Jose, CA, USA).
Subcellular fractionation and cytochrome c immunolocalization
Cells were collected and lysed in hypotonic buffer. Nuclei and unlysed cells were pelleted twice at 200 g for 7 min. The
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resulting supernatants were centrifuged at 10 000 g for 15 min to collect the heavy membrane fraction including the mitochondria. The remaining supernatants were further centrifuged at 100 000 g using a Beckman airfuge (Albertville, MN, USA) for 45 mins. The heavy membrane pellets were dissolved in CCLB and BCA protein assay was performed for both mitochondrial and cytosolic fractions as described above.
Evaluation of caspase-9 activity
Parental JM1 cells, and JM1 cells transfected with WT, S70A or S70E were treated with ara-C or VP-16 for 6 h. Following treatment, cells were collected, and samples normalized to equal cell number. Caspase-9 activity was measured spectrophotometrically using the BioVision caspase assay kit (BioVision) as recommended by the manufacturer.
Results
Bcl-2 is a constitutively phosphorylated protein in many human hematological malignancies 
VEGF upregulates Bcl-2 phosphorylation
VEGF was identified by screening a panel of the factors potentially secreted in CM from either leukemic or stromal cells as a stimulator of Bcl-2 phosphorylation (Figure 3a) . VEGFinduced Bcl-2 phosphorylation was blocked by either PKC or Erk1/2 inhibitors but not the PI-3 K, CDKs, CaM II, or PKA inhibitors evaluated in this study (Figure 3b ). Neutralization of VEGF in either leukemic or stromal cell conditioned media reduced JM1 phosho-Bcl-2 levels compared to media containing an isotype-matched control antibody. JM1 or stromal cell conditioned medium also increased the amount of Mcl-1 protein detected in JM-1 cells with expression diminished when VEGF was neutralized by antibody ( Figure 3c ).
Bcl-2 phosphorylation correlates with cell survival during chemotherapy exposure 
Transfection of phosphomimetic and phosphodeficient Bcl-2 constructs exert opposite effects in JM1 cells
Comparable expression of exogenous murine Bcl-2 protein in human JM1 leukemic cells, and a lack of crossreactivity of either the murine or human-specific Bcl-2 antibody used in this study, was confirmed ( Figure 5a ). As shown in Figure 5b , expression of Phosphorylation blunts caspase-3-mediated cleavage of Bcl-2
Endogenous Bcl-2 cleavage was diminished in JM1 cells transfected with S70E, but not in JM1 cells transfected with S70A (Figure 6a ). JM1 cells expressing WT mBcl-2 had less endogenous hBcl-2 cleavage than that observed in JM1/S70A cells following chemotherapy. Activation of (cleaved) caspase-3 in cells expressing S70E mBcl-2 protein was also less pronounced in JM1/S70E cells (Figure 6b ). In vitro cleavage of immunoprecipitated mouse Bcl-2 protein with active caspase-3 indicated that WT and S70A Bcl-2 were cleaved by active caspase-3, whereas S70E was resistant to proteolysis of Bcl-2 to its 23 kD form (Figure 6c ).
Expression of phosphorylated Bcl-2 is associated with reduction of cytochrome c release and inhibition of caspase-9 activation
In the presence of S70E, release of cytochrome c from mitochondria into the cytosol, triggered by recombinant tBid treatment, was inhibited. Mitochondrial retention of cytochrome c in S70A was lower than that of WT JM1 following tBid treatment (Figure 7a ). Procaspase-9 was maintained near baseline levels in JM1/S70E during VP-16-induced apoptosis (Figure 7b ). Parental JM1 and JM1/S70A cell lysates had less procaspase-9 than identically treated JM1/WT or JM1/S70E. Consistent with Western blot analysis of procaspase-9 protein, caspase-9 activity was increased in parental JM1, or JM1/S70A by either ara-C or VP-16 exposure with a less pronounced increase in JM1/S70E during treatment (Figure 7c ). VP-16 or tBid-induced translocation of cytochrome c into the cytosolic fraction was reduced by VEGF pretreatment of JM1 cells. Negligible cytochrome c was detected in the cytosolic fraction of untreated JM1 cells. Phosphorylation of Bcl-2 protein following VEGF exposure was confirmed in the cell lysates evaluated for cytochrome c (Figure 7d ).
Discussion
The effect of Bcl-2 phosphorylation appears to be very context specific. 25, 26 This is reflected by different effects of Taxol and IL-3-induced Bcl-2 phosphorylation in various models. Taxolinduced S70 Bcl-2 phosphorylation in several tumor cell lines 'inactivates' Bcl-2 and results in apoptotic cell death. 7, 27, 28 In contrast, IL-3-and nicotine-induced phosphorylation of the same residue (S70) can promote cell survival. 13, 29 In both cases, Bcl-2 protein was not constitutively phosphorylated, but was rapidly modified by stress-activated protein kinases (SAPKs) following exposure to various extracellular stimuli. The current study expands investigation of the effect of phosphorylation of Bcl-2 to include human acute lymphoblastic leukemia (ALL) cells. While Bcl-2 can be phosphorylated on multiple sites, either IL-3 or erythropoietin treatment of hematopoietic cells has been shown to result in exclusive phosphorylation of serine 70, suggesting it may be the site that is the most physiologically relevant. 30 A recent report also indicated that bryostatin treatment of B-CLL cells resulted in post-translational phosphor- Western blot of phospho-Bcl-2 in JM1 cells that were serum-starved and pretreated with 5 mM Gö 6983 for 16 h prior to culture in 50 or 100% JM1 or stromal cell conditioned medium. Unconcentrated Iscove's medium (Untr) and concentrated Iscove's medium (Cont. med) were included as controls; '50%' indicates 50% conditioned medium final concentration and '100%' indicates that cells were cultured entirely in media that was preconditioned, by either JM1 or stromal cells as described in Materials and methods.
Bcl-2 phosphorylation in ALL L Wang et al ylation of Bcl-2, associated with increased resistance to druginduced apoptosis. 31 Therefore, we focused on phosphorylation of this residue specifically. However, it should be noted that this study design limits conclusions that can be drawn from our current work to human B lineage ALL, and specifically to the role of phosphorylation of Bcl-2 uniquely at serine 70. The effect of phosphorylation of Bcl-2 at additional single sites, or the influence of multisite phosphorylation was not addressed.
We provide evidence that Bcl-2 exists as a constitutively phosphorylated protein at serine 70 in a variety of human B lineage cell lines and primary leukemic cells (Figure 1a and b) . PKC isoforms were found to be constitutively activated in these tumors, and their activity was required for sustained Bcl-2 phosphorylation (data not shown). The constitutive activation of PKC isoforms in our study is consistent with a recent report which indicated that overexpression of PKC alpha mediates chemoresistance in ALL cells through phosphorylation of Bcl-2, in part, via suppression of PP2A. 32 To better understand the significance of Bcl-2 phosphorylation in a B-lineage leukemia model during stress, we investigated the effects of serum deprivation on phosphorylation.
Serum deprivation rapidly and transiently upregulated Bcl-2 phosphorylation, but reduced phosphorylation of Bcl-2 following long-term incubation (Figure 2a) . The dynamic change in Bcl-2 phosphorylation suggests that Bcl-2 may modulate survival during transient cellular stress. Consistent with a recent report, 14 our data suggest that phosphorylation of Bcl-2 may initiate an 'emergency state' during which cellular machinery necessary for survival can be mobilized. This short-term effect may then provide the cells more time to monitor and/or repair cellular damage before committing to a specific outcome.
Central to our study of the role of phosphorylation of Bcl-2 in Bcl-2 phosphorylation in ALL L Wang et al 3a and b). VEGF has been implicated in promotion of tumor survival in many settings, including an interesting recent report in which stromal cells that produce high levels of VEGF were shown to significantly enhance leukemic cell survival. 33 Potentially, this observation reflects the stromal cells ability to promote tumor cell Bcl-2 activity. VEGF-induced Bcl-2 phosphorylation was blocked by either PKC or Erk1/2 inhibition, suggesting the intrinsic connection of Bcl-2 phosphorylation correlates with cell survival during chemotherapy exposure. (A) Western blot analysis of phospho-Bcl-2 in JM1 cell lysates following Ara-C, VP-16, doxorubicin or 4-HC treatment for 16 h. (B) PP2A activity assay of protein samples from cells treated with chemotherapy exactly as those described above. PP2A activity in each chemotherapy treatment group was compared to that detected in the untreated control sample. Statistical analysis was completed using a Student's t-test. (Figure 3c ). These data suggest that VEGF influences multiple antiapoptotic pathways in human ALL cells, consistent with an earlier report that describes upregulation of Mcl-1 in CMK86 and U937 human leukemia cell lines exposed to the same growth factor. 34 Ara-C, VP-16, doxorubicin and 4-HC exposure all resulted in reduced levels of phospho-Bcl-2 ( Figure 4a ) and increased PP2A activity (Figure 4b ) in JM1 cells. Treatment with a panel of inhibitors that were shown to interrupt phosphorylation of Bcl-2 increased baseline apoptosis of JM1 cells as well as chemosensitivity (Figure 4c) . Availability of the S70A and S70E constructs allowed further evaluation of VP-16 sensitivity as it relates to level of phospho-Bcl-2. Consistent with VEGF-supported phosphorylation of Bcl-2, expression of S70E in JM1 cells resulted in resistance to VP-16 as evaluated by Annexin-FITC staining (Figure 5b) , whereas VEGF-enhanced survival of ALL cells was abrogated by introduction of nonphosphorylatable Bcl-2 (S70A) in JM1 cells (Figure 5c ). Total levels of endogenous human Bcl-2 or transfected murine (WT, S70A or S70E) did not differ significantly, indicating that enhanced survival was not due to altered levels of total Bcl-2 protein but rather expression of the phosphomimetic S70E.
A recent report indicated that the charge that is conferred by phosphorylation of Bcl-2 may blunt its turnover. 30 In that study, cells expressing Bcl-2 were exposed to paclitaxel to induce multisite phosphorylation and subsequently exposed to extracts from staurosporine-treated cells as a source of proteolytic activity. In our B-lineage ALL model, we provide evidence that phosphorylation of Bcl-2 hinders caspase-3-mediated cleavage in vivo (Figure 6a) , and in vitro murine Bcl-2, expressed from the phosphomimetic construct S70E in JM-1 cells, was also resistant to cleavage by recombinant caspase-3 ( Figure 6c ). We have previously reported that chemotherapy induced caspase-3 activity in B lineage leukemic cells. 16 Phosphorylation of Bcl-2, potentially generating a conformational change that results in diminished availability of the caspase-3 recognition site, may block cleavage and help maintain Bcl-2's antiapoptotic function.
In addition to reduced cleavage of S70E Bcl-2 by recombinant caspase-3, we also observed that JM1 cells expressing S70E had reduced activation of endogenous caspase-3 following VP-16 exposure (Figure 6b ). This observation suggested that in JM1 cells, phosphorylated Bcl-2 which is resistant to cleavage may also influence survival upstream of caspase-3 activation. Therefore, we evaluated release of cytochrome c and subsequent caspase-9 activity, key upstream effectors of caspase-3 following Our data indicated that phospho-Bcl-2 expression (S70E) was correlated with reduced release of cytochrome c and activation of caspase-9 during tBid (Figure 7a ) and chemotherapeutic treatment (Figure 7b ). JM1/S70E cells also maintained caspase-9 in its proform more efficiently than the parental or WT-and S70A-transfected lines following treatment with VP-16 or ara-C (Figure 7c) . Potentially, diminished caspase-9 activity may result in reduced caspase-3 activity downstream. These findings support the hypothesis that phospho-Bcl-2 may function at the level of mitochondria to modulate response to intrinsic or external stress. In leukemic cells with constitutively phosphorylated Bcl-2, activation of caspase-9 and -3 may also be interrupted.
To further investigate the potential connection between phosphorylation of Bcl-2 and regulation of mitochondria function, JM1, JM1/WT, JM1/S70A and JM1/S70E were treated with recombinant tBid, a potent apoptosis inducer 35 ( Figure 7a ). The utility of tBid rests, in part, on the fact that it lacks cell cycle phase specificity and therefore allows a broader evaluation of the role of phospho-Bcl-2 in regulation of apoptosis. JM1/S70E cells retained the highest level of mitochondrial cytochrome c, while JM1/S70A cells demonstrated the highest translocation of cytochrome c to the cytosol following tBid treatment (Figure 7a) .
Importantly, VEGF treatment was also able to blunt VP-16-or tBid-induced cytochrome c release from the mitochondria. While tBid or VP-16 treatment of JM1 cells in media alone resulted in easily detectable levels of cytochrome c in the cytosolic fraction, treatment with VEGF resulted in retention of cytochrome c in the mitochondria (Figure 7d ).
Phospho-Bcl-2 may function constitutively in B lineage tumor cells as a contributing factor to initiation of disease, and may also provide a signaling pathway that responds to microenvironment stimuli to promote leukemic cell survival during stress. In addition to a role for VEGF elaborated by bone marrow stromal cells, autocrine production by tumor cells may also enhance survival through a Bcl-2-dependent pathway. Approaches that combine direct targeting of Bcl-2 expression, while also attempting to block signals from the bone marrow microenvironment that modulate its activity may have optimal utility in treatment of ALL. VEGF blunts cytochrome c release from the mitochondria during VP-16 or tBid exposure. (a) Western blot analysis of lysates was completed following subcellular fractionation analysis of JM1 transfectants that were treated with 200 ng/ml tBid for 16 h. Detection of COX subunit II and GAPDH confirmed fraction purity and also served as lane loading controls. (b) Immunoblot of inactive procaspase-9 in parental JM1 cells or JM1 cells that express WT, S70A, or S70E. Cells were treated with VP-16 for 24 h prior to lysis. Procaspase-9:GAPDH ratios, based on densitometric analysis, are shown. (c) Caspase-9 activity assay of parental JM1 and WT, S70A, S70E cells following Ara-C or V-16 treatment. Caspase-9 activity was significantly lower in S70E cells than in all other cells evaluated (Po0.05, Student's t test). (d) JM1 cells were pretreated with 100 ng/ml VEGF and subsequently exposed to either 5 mM VP-16 or 200 ng/ml tBid for 16 h. Western blots were completed to detect Bcl-2 phosphorylation and to quantitate cytochrome c associated with the mitochondrial and cytosolic fraction.
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